← 홈

CGT · 흑색종

22개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 22개
CGTBiologicMerck Sharp & Dohme LLCPhase 3

Recombinant Interferon Alfa-2b (Recombinant Interferon Alfa-2b)

Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8 · HER2

#HER2#CGT#Phase3#인기#세포유전치료+5
임상시험 63상태 ACTIVE
CGTBiologicInge Marie SvanePhase 1

Proleukin (Proleukin)

Melanoma Stage III; Melanoma Stage IV · Melanoma Stage III

#MelanomaStageIII#CGT#Phase1#인기#세포유전치료+5
효능 ORR 33.3%임상시험 59상태 RECRUITING
CGTBiologicMedigen Vaccine Biologics Corp.Phase 1

Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell, Recombinant Oncolytic HSV-2 Therapeutic Injecta, Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF))

Melanoma Stage IV · Melanoma Stage IV

#MelanomaStageIV#CGT#Phase1#인기#세포유전치료+4
임상시험 58상태 ACTIVE
CGTBiologicImmunityBio, Inc.Phase 2

ALT-803 (ALT-803)

Melanoma · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase2#인기#세포유전치료+5
효능 ORR 33%임상시험 56상태 DISCONTINUED
CGTBiologicImmunityBio, Inc.Phase 2

haNK (haNK)

Melanoma · Merkel Cell Carcinoma

#MerkelCellCarcinoma#CGT#Phase2#세포유전치료#CAR-T+4
효능 ORR 5%임상시험 40상태 DISCONTINUED
CGTBiologicstaleMiltenyi Biomedicine GmbHPhase 2

MB-CART19.1 (MB-CART19.1)

Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory · Melanoma Stage III

#MelanomaStageIII#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 7상태 ACTIVE
CGTBiologicstaleTILT Biotherapeutics Ltd.Phase 2

TILT-123 (TILT-123)

Melanoma; Head and Neck Squamous Cell Carcinoma · Melanoma

#Melanoma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 6상태 RECRUITING
CGTBiologicstaleInge Marie SvanePhase 1

ADP-TILIL7 (ADP-TILIL7)

Melanoma Stage III; Melanoma Stage IV · Melanoma Stage III

#MelanomaStageIII#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing Immunochina Medical Sci…Phase 2

AMT-116 CAR-T cells (AMT-116 CAR-T cells)

Melanoma; Non-small Cell Lung Cancer · Melanoma

#Melanoma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleBeijing Immunochina Medical Sci…Phase 2

AMT-253 CAR-T cells (AMT-253 CAR-T cells)

Melanoma; Non-small Cell Lung Cancer · Melanoma

#Melanoma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleErasmus Medical CenterPhase 2

Adoptive therapy with autologous MC2 TCR T cells (Adoptive therapy with autologous MC2 TCR T cells)

Melanoma; Melanoma, Uveal · Melanoma

#Melanoma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

Anti-NY ESO-1 T cell receptor (TCR, Anti-NY ESO-1 T cell receptor, Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells)

Metastatic Cancer; Metastatic Melanoma · Metastatic Cancer

#MetastaticCancer#CGT#Phase2#세포유전치료#CAR-T+3
효능 ORR 4%임상시험 1상태 DISCONTINUED
CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

Anti-NY ESO-1 mTCR PBL (Anti-NY ESO-1 mTCR PBL)

Melanoma; Meningioma · Melanoma

#Melanoma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

Anti-VEGFR2 CAR CD8 plus PBL (Anti-VEGFR2 CAR CD8 plus PBL)

Metastatic Cancer; Metastatic Melanoma · EGFR

#EGFR#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 DISCONTINUED
CGTBiologicShenzhen Geno-Immune Medical In…Phase 2

Antigen-specific CAR T, CTL and DCvac to treat melanoma. (Antigen-specific CAR T, CTL and DCvac to treat melanoma.)

Melanoma · Melanoma

#Melanoma#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING
CGTBiologicstaleJonsson Comprehensive Cancer Ce…Phase 2

F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells (F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells)

Metastatic Melanoma · Metastatic Melanoma

#MetastaticMelanoma#CGT#Phase2#세포유전치료#CAR-T+2
효능 ORR 0%임상시험 1상태 ACTIVE
CGTBiologicstaleShenzhen Geno-Immune Medical In…Phase 2

NG2 and DLL3 CAR-T cells (NG2 and DLL3 CAR-T cells)

Melanoma · Melanoma

#Melanoma#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING
CGTBiologicstaleCentre Hospitalier Universitair…Phase 1

NY-ESO-1 TCR redirected autologous T cell product (NY-ESO-1 TCR redirected autologous T cell product)

Advanced Melanoma; Melanoma Metastatic · Advanced Melanoma

#AdvancedMelanoma#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleUniversity of PennsylvaniaPhase 1

NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1 (NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1)

Multiple Myeloma; Melanoma · PD-1

#PD-1#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 DISCONTINUED
CGTBiologicstaleUniversity of PennsylvaniaPhase 1

T cells modified with RNA anti -cMET CAR (T cells modified with RNA anti -cMET CAR)

Malignant Melanoma; Breast Cancer · Malignant Melanoma

#MalignantMelanoma#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 DISCONTINUED

1 / 2 페이지

← 이전다음 →